Management of Acute Drug Reactions with Pheniramine

Dosing and Administration

The American Academy of Pediatrics recommends administering pheniramine at 1-2 mg/kg IV or IM, with a maximum initial dose of 50 mg, for acute drug reactions including hypersensitivity reactions and dystonic reactions 1
For adult dosing, the IV/IM route is recommended at 1-2 mg/kg per dose, with a maximum initial dose of 50 mg 1
The oral route may be used when appropriate, with a dose of 4-12 mg as a single nocturnal dose for ongoing allergic conditions 2

IV administration should be given slowly over 2-3 minutes to avoid pain at the injection site and reduce the risk of seizures 1
The IM route is acceptable when IV access is not immediately available 1
Pheniramine serves as an adjunctive medication alongside epinephrine and hydrocortisone in managing anaphylactic reactions, not as primary therapy 2

Sedation is the most common side effect and should be anticipated 1, 2
Respiratory suppression may occur, particularly when combined with other sedative agents 1
Paradoxical excitement or agitation can develop, especially in younger children 1
Hypotension may occur, particularly with rapid administration 1
Avoid use in severe hepatic disease, as sedative effects may precipitate hepatic coma 2
Contraindicated in angle-closure glaucoma, prostatic hypertrophy, and urinary retention 2, 3
Avoid concomitant use with MAOIs and medications with anticholinergic effects 2, 3

Pregnancy: Should be avoided, especially during the first trimester, despite a long safety history 2, 3
Elderly patients: Start with lower doses due to increased sensitivity to anticholinergic effects 3
Lactation: Should be avoided 2

Monitor vital signs and oxygen saturation during and after administration 1
Be prepared to provide respiratory support, as there is an increased risk of apnea when pheniramine is combined with other sedative agents 1
Watch for paradoxical agitation, particularly in pediatric patients 1
Avoid combining pheniramine with other anticholinergic medications or MAOIs to prevent additive toxicity 2, 3

The American Society of Clinical Oncology recommends that pheniramine should never be used as monotherapy in anaphylaxis, and epinephrine must be given first, with pheniramine serving as adjunctive second-line therapy after epinephrine and fluid resuscitation, and combination with H2-blockers is superior to H1-antihistamine alone in managing infusion reactions 4

Pheniramine maleate for intramuscular injection is supplied in a ready‑to‑inject concentration and should be drawn directly from the ampule without any diluent. 5
The standard adult dose for acute allergic reactions and anaphylaxis is 10 mg IM (approximately 1 mL). 5
Pediatric age‑based dosing is recommended for practical administration:
- > 12 years: 10 mg IM
- 6–12 years: 5 mg IM (≈0.5 mL)
- 6 months–6 years: 2.5 mg IM (≈0.25 mL)
- < 6 months: 250 µg/kg IM

No dilution is required for intramuscular use; dilution is only indicated when preparing a slow intravenous push (over 2–3 minutes). 7

Epinephrine must be administered first in anaphylactic reactions; pheniramine is an adjunctive therapy and should be given after epinephrine and fluid resuscitation. 8
Pheniramine alleviates urticaria and pruritus but does not treat bronchospasm, laryngeal edema, or hypotension. 8
The recommended timing is to give pheniramine after initial stabilization with epinephrine (e.g., 50 µg IV bolus for adults or 0.01 mg/kg IM for children). 5
It is typically administered concurrently with hydrocortisone as part of secondary management. 5

Respiratory depression may occur, especially when pheniramine is combined with other sedatives (e.g., benzodiazepines or opioids). 7
Continuous monitoring of vital signs and oxygen saturation is advised; be prepared to provide respiratory support if apnea develops. 7

Dilution errors: Diluting pheniramine for intramuscular injection is unnecessary and can lead to dosing mistakes. Only dilute when a slow IV push is intended. 7
Therapeutic misunderstanding: Pheniramine must never replace epinephrine in anaphylaxis, as it does not address life‑threatening airway or circulatory compromise. 8